Royal Bank Of Canada Issues Positive Forecast for Medline (NASDAQ:MDLN) Stock Price

Medline (NASDAQ:MDLN) had its price objective lifted by Royal Bank Of Canada from $47.00 to $53.00 in a report published on Thursday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock.

Other equities research analysts also recently issued research reports about the company. Evercore restated an “outperform” rating and set a $55.00 price target on shares of Medline in a report on Wednesday. Mizuho started coverage on shares of Medline in a report on Monday, January 12th. They issued an “outperform” rating and a $48.00 target price on the stock. UBS Group assumed coverage on shares of Medline in a research note on Monday, January 12th. They issued a “buy” rating and a $48.00 price target for the company. Sanford C. Bernstein began coverage on shares of Medline in a research report on Monday, January 12th. They issued an “outperform” rating and a $49.00 price objective on the stock. Finally, Wells Fargo & Company began coverage on shares of Medline in a research report on Monday, January 12th. They set an “equal weight” rating and a $42.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Medline currently has an average rating of “Moderate Buy” and an average target price of $50.15.

Medline Trading Up 1.5%

Shares of MDLN opened at $48.89 on Thursday. Medline has a fifty-two week low of $34.89 and a fifty-two week high of $50.88. The business’s 50 day simple moving average is $44.40.

Medline (NASDAQ:MDLN) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.24 by ($0.25). The business had revenue of $7.79 billion for the quarter, compared to the consensus estimate of $7.52 billion. Medline’s revenue was up 14.8% on a year-over-year basis.

Insider Transactions at Medline

In other news, Director Charles N. Mills purchased 2,579,310 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The shares were purchased at an average price of $29.00 per share, for a total transaction of $74,799,990.00. Following the purchase, the director directly owned 2,441,379 shares of the company’s stock, valued at $70,799,991. This represents a -1,870.00% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Andrew J. Mills purchased 2,586,206 shares of the business’s stock in a transaction on Thursday, December 18th. The shares were purchased at an average cost of $29.00 per share, for a total transaction of $74,999,974.00. Following the transaction, the director owned 2,586,206 shares of the company’s stock, valued at $74,999,974. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

Hedge Funds Weigh In On Medline

Institutional investors have recently modified their holdings of the business. Kera Capital Partners Inc. purchased a new stake in Medline in the 4th quarter valued at $3,785,000. Virtu Financial LLC acquired a new position in Medline in the fourth quarter valued at $2,243,000. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Medline in the fourth quarter valued at about $298,461,000. Invesco Ltd. acquired a new stake in shares of Medline during the fourth quarter worth about $106,239,000. Finally, Corient Private Wealth LLC acquired a new stake in shares of Medline during the fourth quarter worth about $229,000.

Key Headlines Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Multiple major firms raised price targets and ratings following Q4 — Citigroup to $60 (buy), UBS to $57 (buy), BMO to $54 (outperform) and RBC to $53 (outperform). These upgrades signal renewed analyst conviction and likely support near‑term buying interest.
• Positive Sentiment: Q4 revenue beat and strong growth: Medline reported Q4 net sales of ~$7.8B (up 14.8% YoY) and full‑year net sales of $28.4B, driven by new customer signings — a validation of the company’s scale and demand. Medline Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Management issued 2026 guidance calling for Organic Sales growth of 8–9% and Adjusted EBITDA of $3.5–$3.6B, which supports a positive growth narrative despite near‑term margin headwinds. Medline Reports Fourth Quarter and Full Year 2025 Results
• Neutral Sentiment: Analyst coverage roundup and notes on upgraded forecasts after Q4 provide context for the rating moves but aggregate guidance and assumptions vary by shop. Medline Analysts Boost Their Forecasts Following Q4 Results
• Neutral Sentiment: Earnings call and transcript are available for detailed read‑throughs of management’s commentary on customer wins, supply‑chain actions and cost drivers. Medline Inc. (MDLN) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Valuation pieces are appearing as shares move; some note momentum but also emphasize the need to weigh price against near‑term margin pressure. Assessing Medline (MDLN) Valuation After Recent Share Price Momentum
• Negative Sentiment: Earnings per share missed consensus — reported ($0.01) vs. street ~$0.24 — driven by higher cost of goods sold, tariffs and IPO-related expenses; this explains some investor caution on near‑term profitability. Medline Q4 Press Release / Financial Tables
• Negative Sentiment: Net income and adjusted margins were down (Q4 net income -37.7% YoY; Adjusted EBITDA roughly flat) and management cited tariff, inventory and investment costs — risks that could compress margins if cost pressures persist. Quiver Quant Summary

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.